The U.S. Food and Drug Administration (FDA) has issued a proposed rule that would speed the dissemination of new safety information about generic drugs to health professionals and patients by allowing generic drug makers to use the same process that brand-name drug manufacturers use to update product label safety information; they would be permitted to update product labeling with newly acquired safety information before FDA reviews the change. The rule would also require generic manufacturers to inform the brand-name manufacturers about the change. Under the new rule, “brand and generic drug products would ultimately have the same FDA-approved prescribing information.” Comments are requested by January 13, 2014. See Federal Register, November 13, 2013.